The Tetraphase platform provides the company with a broad-range of commercial opportunities across a number of significant disease categories. The Company’s initial focus is on the discovery and development of novel antibiotics to treat drug-resistant infections, a growing threat to public health. This technology also provides meaningful commercial opportunities in inflammation and oncology.

The company’s business strategy is to:

> Expand on a novel synthetic chemistry platform, aiming to become a leading innovator in the discovery and development of a portfolio of novel antibiotics with potent activity against drug resistant infections;

> Leverage the known properties of the tetracycline class in key areas of unmet medical and clinical need including inflammation and oncology.

> Exploit the full potential of each new chemical entity and bring innovative new products to market through corporate alliances and partnering strategies.